Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAILOR-PANC: Molecularly Tailored Therapy Versus Standard Care in Advanced Pancreatic Cancer
NCT07802418Phase 2Not yet recruiting
- Sponsor
- Herlev Hospital
- Start
- Oct 2026
- Primary completion
- Jun 2031
- Countries
- 1
01
Overview
A Phase 2 trial of axitinib, crizotinib, dabrafenib + trametinib, trametinib, erlotinib in pancreatic cancer (PC), sponsored by Herlev Hospital. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
axitinibcrizotinibdabrafenib + trametinibtrametiniberlotinib
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07802418.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07802418.